Shanghai - Delayed Quote CNY

Xiamen Amoytop Biotech Co., Ltd. (688278.SS)

Compare
80.88
+0.79
+(0.99%)
At close: January 27 at 3:00:02 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
NameTitlePayExercisedYear Born
Mr. Li Sun Chairman & GM -- -- 1966
Ms. Yiling Yang Financial Director, Deputy GM, Secretary of the Board, & CFO -- -- 1975
Ms. Liping Lai Director & Deputy GM -- -- 1971
Ms. Meihua Yang Deputy General Manager -- -- 1972
Mr. Jiehua Zheng Deputy General Manager -- -- 1980
Mr. Weidong Zhou Deputy General Manager -- -- 1971
Mr. Linzhong Zhang Deputy General Manager -- -- 1969
Mr. Fanghe Chen Deputy General Manager -- -- 1965
Ms. Shiyuan Wang Technical Director of R&D Center -- -- 1973
Ms. Ping Zou Director of Intellectual Property Management -- -- 1966

Xiamen Amoytop Biotech Co., Ltd.

No. 330 Wengjiao Road
Xinyang Industry Zone Haicang
Xiamen, 361028
China
86 59 2688 9114 https://www.amoytop.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
1,960

Description

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.

Corporate Governance

Xiamen Amoytop Biotech Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

May 23, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers